Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Orthopedic Sugery
  •  Trauma
  •  Emergency Medicine and Critical Care
  •  Pathology
  •  Nephrology
  •  Hematology
  •  Obstetrics and Gynecology
  •  Cardiac Surgery


Citation: Ann Clin Case Rep. 2021;6(1):2063.DOI: 10.25107/2474-1655.2063

Demyelinating Disease after Anti-tumor Necrosis Factor Alfa Treatment

Refah Sayın1*, Muhammed Ertuğrul Güvenç1 and Mehmet Zülküf Önal2

1Department of Neurology, Ufuk University, Turkey
2Department of Neurology, Medicana International Ankara Hospital Neurology, Turkey

*Correspondance to: Refah Sayın 

 PDF  Full Text Case Report | Open Access


Certolizumab is a Tumor Necrosis Factor alpha (TNF-α) inhibitor. It is a biological medicine used for the treatment of Crohn's disease, Rheumatoid Arthritis (RA), psoriatic arthritis and Ankylosing Spondylitis (AS). Although certolizumab has many reported side effects, neurological side effects are rare. Suicide attempt, mental disorder, delirium, hearing-vision and facial nerve inflammation, epileptic seizure, coordination and/or balance disorder, paralysis, acute inflammatory demyelinating polyneuropathy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), peripheral neuropathy and Optic Neuritis (ON) are possible visible effects. Peripheral neuropathy is the most common; Central Nervous System (CNS) and/or medulla spinalis demyelination follows this. While other TNF-α inhibitors (Adalimumab, Infliximab, Etanercept, Golimumab) are used in the treatment of RA, they have been reported to cause demyelinating disease or Guillain-Barre Syndrome (GBS). With certolizumab treatment, the risk of CNS and/or medulla spinalis demyelination or peripheral neuropathy is known and very rare. We aimed to present a case of demyelinating disease secondary to the rare use of certolizumab.


Cite the Article:

Sayın R, Güvenç ME, Önal MZ. Demyelinating Disease after Anti-tumor Necrosis Factor Alfa Treatment. Ann Clin Case Rep. 2021; 6: 2063..

Search Our Journal

Journal Indexed In

Articles in PubMed

Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and other Naturally Occurring Compounds, Part I
 PubMed  PMC  PDF  Full Text
Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and Naturally Occurring Compounds, Part II
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Clinical Evidence for the Use of Methylone in the Treatment of PTSD: A Case Series with Long-Term Follow- Up
 Abstract  PDF  Full Text
Treatment of Lower Limb Movement Disorder in Complete Paraplegia Caused by Spinal Cord Injury with Spinal Neuromodulation: A Case Report
 PDF  Full Text
View More...